These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 4089829

  • 21. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: an experimental study in two models of thrombosis in the rabbit.
    Amar J, Caranobe C, Sie P, Boneu B.
    Br J Haematol; 1990 Sep; 76(1):94-100. PubMed ID: 2223652
    [Abstract] [Full Text] [Related]

  • 22. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit.
    Carrie D, Caranobe C, Gabaig AM, Larroche M, Boneu B.
    Thromb Haemost; 1992 Dec 07; 68(6):637-41. PubMed ID: 1287877
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation.
    Van Ryn-McKenna J, Ofosu FA, Hirsh J, Buchanan MR.
    Br J Haematol; 1989 Feb 07; 71(2):265-9. PubMed ID: 2522314
    [Abstract] [Full Text] [Related]

  • 30. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis.
    Iacoviello L, D'Adamo MC, Pawlak K, Polishchuck R, Wollny T, Buczko W, Donati MB.
    Thromb Haemost; 1996 Dec 07; 76(6):1102-7. PubMed ID: 8972038
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.
    Ortel TL, Gockerman JP, Califf RM, McCann RL, O'Connor CM, Metzler DM, Greenberg CS.
    Thromb Haemost; 1992 Mar 02; 67(3):292-6. PubMed ID: 1379384
    [Abstract] [Full Text] [Related]

  • 35. Lack of correlation between "in vitro" and "in vivo" antithrombotic activity of heparin fractions and related compounds. Heparan sulfate as an antithrombotic agent "in vivo".
    Bianchini P, Osima B, Parma B, Nader HB, Dietrich CP.
    Thromb Res; 1985 Dec 01; 40(5):597-607. PubMed ID: 4089830
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J, Stehle G, Blauth M, Huck K, Mall K, Heene DL.
    Semin Thromb Hemost; 1997 Dec 01; 23(1):83-90. PubMed ID: 9156415
    [Abstract] [Full Text] [Related]

  • 38. Inhibition of intimal hyperplasia after arterial injury by heparins and heparinoid.
    Dryjski M, Mikat E, Bjornsson TD.
    J Vasc Surg; 1988 Nov 01; 8(5):623-33. PubMed ID: 2460647
    [Abstract] [Full Text] [Related]

  • 39. Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.
    Ofosu FA, Modi GJ, Blajchman MA, Buchanan MR, Johnson EA.
    Biochem J; 1987 Dec 15; 248(3):889-96. PubMed ID: 2963622
    [Abstract] [Full Text] [Related]

  • 40. Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin.
    Herbert JM, Hérault JP, Bernat A, van Amsterdam RG, Vogel GM, Lormeau JC, Petitou M, Meuleman DG.
    Circ Res; 1996 Sep 15; 79(3):590-600. PubMed ID: 8781492
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.